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Renal receptors and effects of atrial natriuretic factor in compensatory
renal hypertrophy. In the present study we investigated the in vivo and
in vitro renal responsiveness to ANF, and the adaptation of ANF
receptors in compensatory renal hypertrophy in the rat. One week after
left nephrectomy (UNx), plasma levels of immunoreactive ANF, blood
pressure (MAP), hematocrit (Hct), and urine flow rate (V) were
unaltered compared to control (C) rats. Baseline GFR and potassium
excretion (UKV) were significantly higher, and sodium excretion
(UNaV) tended to be elevated in UNx rats. Administered ANF led to
similar dose-related decreases in MAP and increases in Hct in UNx and
C rats. However, at each dose of infused ANF, absolute values and the
increase in GFR and UNaV were higher in UNx than in C rats.
Hypertrophied (H) kidneys were removed from UNx and perfused
in vitro to determine distribution and density of ANF receptors,
responsiveness to ANF, and receptor-mediated organ clearance of
'251-ANF128. The density of ANF receptors in cortex, outer medulla,
and papilla of H kidneys was not significantly different from that in C
kidneys. In H isolated kidneys, ANF led to dose-related increases in
GFR, V, UNaV, and UKV that were indistinguishable (P> 0.05) from
those in C kidneys. Receptor-mediated organ clearance of '251-ANF128
in isolated H kidneys was 2.8 .02 mI/mm, a value not significantly
different (P> 0.05) from that in C kidneys. The results demonstrate that
the number of renal receptors of ANF increases in proportion to kidney
weight in compensatory hypertrophy, leading to a normal intrarenal
distribution and receptor density, as well as preserved responsiveness
to ANF and receptor-mediated clearance of the hormone. This adapta-
tion, together with systemic factors that lead to the enhanced respon-
siveness to ANF in vivo, may contribute importantly to the preserva-
tion of sodium volume homeostasis in compensatory hypertrophy.
There are two major classes of ANF receptors in the mam-
malian organism, named BA-ANF (or R1-ANF, or GCA-ANF)
and C-ANF (or R2-ANF) receptors [1—9]. BA-ANF receptors
are coupled to the generation of cGMP and mediate the biolog-
ical actions of ANF. C-ANF receptors are not coupled to the
generation of cGMP and do not mediate any of the known
cardiovascular and renal effects of the hormone. Previous
studies from our laboratory demonstrated that C-ANF recep-
tors are importantly involved in the removal of ANF from the
circulation [8, 10]. In this manner they play an important role in
determining the plasma levels and plasma homeostasis of ANF.
C-ANF receptors constitute the overwhelming majority (>
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95%) of the total population of ANF receptors in the kidney and
the vasculature [1, 2, 6, 11]. Regulation of the two classes of
ANF receptors may play an important role in the sensitivity to
the renal effects of the hormone and/or in the clearance of ANF
from the circulation. However, evidence for up or down regu-
lation of BA-ANF or C-ANF receptors has been sparse and
contradictory [12—16].
In the present work we investigated the sensitivity of hyper-
trophied kidneys to the effects of ANF, and whether ANF
receptors are able to adapt to rapid renal growth induced by
contralateral nephrectomy. For this purpose we determined the
dose-response curves of ANF effects in unilaterally nephrecto-
mized rats and in isolated perfused rat kidneys removed from
rats that had undergone renal compensatory hypertrophy. In
addition we determined the density of ANF receptors in cortex,
medulla and papilla, and the receptor-mediated organ clearance
(extraction) of ANF in the isolated perfused rat kidney. The in
vivo data show that at each dose of administered ANF, GFR
and fluid and electrolyte excretion in hypertrophied kidneys
were significantly greater than in controls. The in vitro data
show that in hypertrophied kidneys the increase in number of
ANF receptors in cortex, outer medulla, and papilla is propor-
tional to the increase in kidney weight, resulting in normal
receptor densities, appropriate dose-response curves of the
renal effects of ANF, and unchanged receptor-mediated organ
clearance of the hormone.
Methods
Materials
Rat ANF128 was purchased from Peninsula Laboratories, or
provided by Dr. John Lewicki, California Biotechnology Inc.
(Mountain View, California, USA). ANF128 was labeled with
[12511 using a modified chloramine-T procedure, as previously
described [17, 18], The monoiodinated form was purified by
high pressure liquid chromatography (HPLC) using a C18
Bondapak reverse phase column and a linear gradient of 10 to
60% acetonitrile, as previously described [17]. More than 95%
of the purified labeled 1251-ANF128 (specific activity of 2000
Ci/mmol) eluted as a single peak. 4C-Carboxy-Inulin and
carrier-free '25INa were purchased from New England Nuclear
Inc. (Boston, Massachusetts, USA). Fraction V albumin was
acquired from ICN (Cleveland, Ohio, USA). Unless otherwise
indicated, all other reagents were purchased from Sigma Chem-
ical Co. (St. Louis, Missouri, USA).
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Experimental animals
Male Sprague-Dawley rats (285 to 330 g) were used for
studies of the effects of administered ANF in vivo, for mea-
surements of plasma levels of immunoreactive ANF, or as
donors for the isolated perfused rat kidney. One week before
perfusion, rats in the experimental group were anesthetized
with ketamine (0.1 mi/tOO g body wt) and acepromazine (0.01
ml/l00 g body wt), and the left kidney was removed through a
dorsal approach. Unoperated rats served as controls. In studies
on the determination of the effect of unilateral nephrectomy on
kidney mass, the left kidney was removed as described above,
freed of attached tissues and weighed; one week after nephrec-
tomy the procedure was repeated for the right kidney. In
studies on the effects of uninephrectomy on plasma levels of
immunoreactive ANF, immediately before the removal of the
left kidney as described above, blood samples (1.5 ml) from
unanesthetized rats, were collected from the tail vein in chilled
tubes containing potassium EDTA. One week after uninephrec-
tomy, blood collection was repeated in the same manner.
Unoperated rats served as controls. Plasma immunoreactive
ANF was determined by radioimmunoassay of plasma ex-
tracted by filtration through C18 Sep-Pak cartridges (Waters
Associates, Rochester, Minnesota, USA), as previously de-
scribed [8].
Dose-response effects of ANF in anesthetized rats
Effects of ANF on renal function and blood pressure were
observed in uninephrectomized and control rats anesthetized
with 100 mg/kg body wt, i.p., of mactin (Promonta, Germany).
Throughout the experiments animals were warmed to keep a
rectal temperature of 38°C. The trachea was cannulated with a
PE 240 polyethylene catheter. PE 50 catheters were introduced
in the femoral veins for administration of fluid, 14C-inulin and
ANF128, and into the carotid and femoral arteries for the
measurement of arterial blood pressure and collection of arte-
rial blood samples. The abdominal cavity was exposed for the
cannulation of the right ureter in experimental animals and of
the right and left ureters in control animals with PE 10 tubing.
To replace surgical losses of fluid, fresh rat plasma obtained
from littermate rats was infused at a rate of 0.1 mi/mm up to a
total volume corresponding to 1.2% of body weight. Ringer's
bicarbonate solution was infused at a rate of 50 d/min through-
out the experiment in control and experimental rats. After
completion of plasma infusion, '4C-inulin (New England Nu-
clear) was administered i.v. as a prime (2 pCi) followed by a
constant infusion of 2 MCi/hr. An equilibration period of 60
minutes was allowed before measurements were started. After
two 10-minute control periods, experimental rats received
ANF128 dissolved in Ringer's bicarbonate. Increasing doses of
the peptide were administered at sequential infusion rates of
0.02, 0.1 and 1 g/min/kg body wt. Immediately prior to each of
these infusion rates, ANF128 was administered as a bolus of
0.2, 1, and 10 pg/kg body wt, respectively. A five minute
equilibration was allowed before the start of 10 minute clear-
ance periods at each dose of ANF. After the termination of the
clearance period with the highest dose of ANF, two 20-minute
recovery periods were performed. Blood samples (0.2 ml) were
collected at the mid-point of each clearance period, along with
blood collection in glass capillaries for measurements of hema-
tocrit. Blood pressure was recorded continuously.
Glomerular filtration rate (GFR) was determined by the
clearance of '4C-inulin. Sodium and potassium in plasma and
urine were measured by flame photometry. Urine volume was
determined gravimetrically.
Isolated perfused rat kidney
In experimental and control groups, the right kidney was
isolated and perfused as previously described by our laboratory
[19]. Briefly, after anesthetizing the rats with mactin
(Promonta, Germany, 100 mg/kg i.p.), the right renal artery was
cannulated by way of the mesenteric artery without interruption
of flow. Then the kidney was removed from the rat and placed
in a closed circuit perfusion-oxygenation system where perfu-
sion was carried out at 37°C. The system contained 60 ml of
perfusate consisting of Krebs-Henseleit bicarbonate buffer con-
taining fraction V bovine serum albumin, creatinine (0.5 mgI
ml), glucose (1 mg/mi), and a mixture of amino acids, as
previously described [19]. The perfusate was gassed with a
mixture of 95% 02-5% CO2 and the pH adjusted to 7.4.
Non-filtering kidneys were perfused at an effective perfusion
pressure (pressure at the tip of the cannula) of 70 to 80 mm Hg
with a perfusate containing 10 g/dl albumin. Filtering kidneys
were perfused at an effective perfusion pressure of 90 to 100mm
Hg with a perfusate containing 7.5 g/dI albumin. Filtering and
nonfiltering kidneys were perfused initially for 30 minutes
before the addition of labeled and/or unlabeled ANF128.
Binding studies in isolated perfused rat kidneys
Equilibrium binding studies were performed with saturating
concentrations of ANF128 in control (N 6) and experimental
(N = 4) nonfiltering isolated perfused rat kidneys as previously
described [17]. Briefly, 1251-ANF128 (1 to 2 MCi, perfusate
concentration = 0.5 to 1 pM) and ANF128 (perfusate concen-
tration, 1 flM) were added to perfusate simultaneously, 30
minutes after starting the perfusion. Previous studies from our
laboratory have shown that near saturation of binding is at-
tained at a perfusate ANF128 concentration of 1 flM in control
kidneys [17]. Pilot experiments demonstrated that, in control
and experimental kidneys, specific binding of ANF in the
isolated kidney did not differ if 10 flM instead of 1 nM of ANF128
was added to the perfusate. Kidneys were perfused with the
hormone for 30 minutes, a time previously shown to be suffi-
cient to reach equilibrium binding [17]. One ml of perfusate
samples was collected at several time intervals during perfusion
and placed on ice. At the end of perfusion, the kidney was
placed on an ice cold plate and sections of outer cortex (C),
outer medulla (OM), and papilla (P) were dissected and rapidly
weighed to a precision of 0.01 mg, as previously described [17].
Perfusate samples were precipitated with an equal volume of
12% ice-cold trichloroacetic acid (TCA). Following centrifuga-
tion the precipitates were resuspended in 1 ml of 12% solution
of TCA, and recentrifuged. Radioactivity in precipitates, com-
bined supernatants, and kidney tissues (C, OM and P) was
determined in a gamma spectrometer. The nature of the radio-
activity in perfused samples and in acid wash of the isolated
kidney was determined by reverse phase HPLC, as previously
described [17]. As previously shown [17], radioactivity bound
to kidney tissue, and the TCA precipitable radioactivity in
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perfusate eluted in reverse phase HPLC as intact '25I-ANF128.
The specific activity of the labeled peptide (DPM TCA precip-
itable radioactivity/pmol ANF) remained nearly constant during
the 30 minutes of perfusion.
Dose-response experiments in isolated perfused rat kidneys
The dose-response effects of ANF128 on renal vascular
resistance (RVR), renal perfusate flow (RPF), glomerular filtra-
tion rate (GFR), filtration fraction (FF), urine flow rate (V), and
the absolute and fractional excretion of sodium and potassium
were determined in filtering isolated perfused rat kidneys as
previously described [8, 17]. In these experiments, Ito 2 iCi of
'4C-inulin were added to perfusate at the beginning of the
experiment. After kidneys were perfused for 30 minutes for
equilibration, two 10-minute control clearance periods were
performed. Then, increasing amounts of ANF128 were added to
the perfusate to give final perfusate concentrations of 10— 10 to
i0 M. A five minute equilibration was allowed after the
addition of each concentration of ANF, before a 10-minute
clearance period was performed. Perfusate samples were col-
lected at the mid-point of each clearance period. Sodium and
potassium concentrations in urine and perfusate were deter-
mined by flame photometry. Urine volume was determined
gravimetrically. Perfusate and urine 14C-inulin were determined
by liquid scintillation spectroscopy.
Organ clearance of '251-ANF128 in isolated perfused rat
kidneys
Organ clearances of 125I-ANF128 were determined in four
hypertrophied and four control non-filtering isolated rat kidneys
from the perfusate decay curves of TCA precipitable radioac-
tivity. For this purpose, 1 to 2 tCi of '251-ANF128 were added
to the perfusate to give a final concentration of ANF,28 of 10
p, which is well below saturation of ANF receptors in the
isolated kidney [17]. Two minutes were allowed for homoge-
nous distribution of the added labeled peptide in the recirculat-
ing perfusate, before the first perfusate sample was taken (time
zero). Then, 1 ml perfusate samples were collected at several
time intervals, up to 30 minutes after the addition of '251-ANF1
28. Perfusate samples were precipitated with 12% TCA as
described above.
Calculations
Whole animal experiments.The clearance of inulin and the
excretion of fluid, sodium and potassium were calculated by
standard formulas.
Isolated perfused rat kidney experiments.ANF bound to C,
OM, and P (in pmoles) was calculated by the amount of
'251-ANF128 (in DPM) in these kidney tissues divided by the
specific activity of the labeled peptide in the perfusate (in
DPM/pmol) [17]. In separate experiments, we confirmed [17]
that nonspecific binding (binding of '25I-ANF128 in the pres-
ence of iø M ANF128) was less than 5% of total binding.
Therefore, total binding of '251-ANF128 was considered to
represent specific binding. As experiments were performed at
saturating concentrations of ANF128, ANF bound to C, OM,
and P represent the total amount of ANF receptors in these
regions. The density of ANF specific binding sites in C, OM,
and P were calculated by ANF bound (in pmoles) per wet tissue
weight (in g). RVR was calculated by the ratio RPF/effective
perfusion pressure. GFR was considered to be equal to the
clearance of '4C-inulin, which was calculated in a standard
manner. Filtration fraction (FF), absolute excretion of sodium
(UNaV), absolute excretion of potassium (UKV), fractional
excretion of Na (FENa) and fractional excretion of K (FEK)
were also calculated by standard formulas. The ED50 is defined
as the perfusate concentration of ANF128 required to produce
half-maximal response for a given renal effect. The organ
clearance (E) of '251-ANF128 was calculated by the formula E
= kV, were k is initial (first 15 mm of perfusion) rate constant
(in min1) of the exponential perfusate decay curve of TCA
precipitable radioactivity, and V is the volume (in ml) of the
perfusate.
Results are expressed as mean SE. Statistical comparisons
between groups were performed by Student's t-test. A P value
of less than 0.05 was considered statistically significant.
Results
Whole rat experiments
In eight rats (333 6 g body wt), weights of the right and left
kidney were practically identical (1.26 0.05 g and 1.27 0.05
g, respectively), and similar to the left kidney weight of 1.23
0.04 (N = 21) in all rats that served as donors for the isolated
kidney (P > 0.05). In a separate group of four rats, the right
kidney weight increased by approximately 20%, from 1.22
0.03 to 1.47 0.03 g (P < 0.001) one week after left nephrec-
tomy, whereas body weight increased by only 3%, from 391
4 to 328 3 g. The increase in contralateral kidney weight was
similar to that found by other investigators, who also reported
that the ratio of kidney weight/body weight was maximal one
week after unilateral nephrectomy [20].
In experimental rats, plasma immunoreactive ANF at one
week after uninephrectomy was 130 39 pg/mi (N = 4), a value
not significantly different (P > 0.05, paired t-test) from that
measured immediately before uninephrectomy in the same rats
(134 63 pg/mi). In control rats (N = 6), plasma levels of
immunoreactive ANF at day 0 (170 55 pg/mi) were also not
significantly different (P > 0.05 paired t-test) from those at day
7 (124 32). Furthermore, there was no significant difference
(P > 0.05, independent t-test) between plasma immunoreactive
ANF in control and experimental rats at day 0 or 7.
Table 1 summarizes the results of the studies on baseline and
dose-related effects of ANF on mean arterial blood pressure
(MAP), hematocrit (Hct), and renal functions in control and
uninephrectomized rats. Baseline MAP and Hct were similar in
both group of rats, whereas GFR and UKV were significantiy
higher in uninephrectomized than in control rats. The average
values for baseline V and, particularly, UNaV, were also higher
in uninephrectomized rats, but the variability of these parame-
ters was relatively high, resulting in lack of statisticaliy signif-
icant differences between the two groups. In uninephrectomy
and control groups, ANF infusion led to dose-related decreases
in MAP and increases in Hct, GFR, fluid and electrolyte
excretion. In general, these parameters recovered to near
baseline values in the second recovery period (20 to 40 minutes
after cessation of ANF infusion). Even at the lowest dose (0.02
jsg/min/kg body wt) the effects of ANF on all measured func-
tional parameters were apparent. Maximal, statistically signifi-
cant decreases in MAP, and increases in GFR, V, UNaV and
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Table 1. Dose-response curve of ANF effects in control and unilaterally nephrectomized rats
ANF,.,,
ixg/kg/min
BP
mm Hg
Hct
%
GFR
mi/mm
v
pi/min
UNaV UKV
Eq/min
Controls N = 6
0 118 2.8 37.6 2.9 1.74 0.08 9.2 4.3 0.24 0.07 1.21 0.31
0.02 109 27b 38.5 3.3 1.88 0.18 17.5 4.6 1.12 0.42 1.90 0.47
0.10 97 5.0' 41.3 3.1 2.27 0.14' 32.2 56b 5.18 0.69" 2.53 023b
1.00 92 2.7" 41.0 3.9 2.18 0.19 23.8 4.4" 5,19 0.86" 2.07 0.29
Recovery 99 25" 37.0 1.1 1.85 0.13 27.2 8.5 1.87 0.39" 0.98 0.18
Nephrectomized N = 5
0 123 3.4 35.5 1.0 2.08 0.l3 11.6 2.4 0.65 0.26 2.26 0.28a
0.02 118 3.2 36.5 1.3 2.47 0.24 28.9 9.7 2.41 075b 2.98 0.51
0.10 106 36b 38.3 10b 3.08 012a,b 46.2 73b 8.30 112a.b 3.69 038a.b
1.00 96 4.8" 39.8 13b 3.15 O.24a 39.7 7.7" 8.62 137a,b 3,73 057a.b
Recovery 101 3.3" 36.5 1.5 2.28 0.21 20.4 5.8 3.46 0.99'' 2.31 0.49a
Values are mean SE of 6 control and 5 hypertrophied kidneys, except for Hct where 4 control and 4 hypertrophied kidneys are used.
Abbreviations are: 0, control periods before the addition of ANF,28; R, second recovery period (20—40 mm after cessation of the ANF infusion);
BP, mean arterial blood pressure; Hct, hematocrit; GFR, glomerular filtration rate; V, urine flow rate; and UNaV and UKV, urinary excretion rates
of sodium and potassium, respectively.
'P < 0.05 vs. corresponding value in control rates
b P < 0.05 vs. control period of the same group.
UKV were obtained at the intermediate dose of ANF (0.1
g!minIkg body wt). A tenfold increase in this dose to 10
.tgIminIkg body wt resulted in no further significant changes in
the measured functional parameters in uninephrectomized or
control rats. ANF had quantitatively similar and relatively
small dose-related effects on MAP and Hct in both groups.
However, at each dose of ANF, the absolute values of GFR, V,
UNaV and UKV were higher in uninephrectomized than in
control rats. This difference reached statistical significance at
the intermediate and high doses of the hormone. Figure 1 shows
that, in addition, ANF-induced increases in GFR and UNaV
from baseline values had a tendency to be higher in uninephrec-
tomized than in control rats, particularly at the intermediate and
high doses of the hormone.
Isolated perfused rat kidney experiments
Figure 2 shows the values for the density of ANF receptors in
C, OM and P in control (N = 6) and hypertrophied (N = 4)
non-filtering isolated kidneys. The density of ANF receptors in
control rats was: C = 6.1 0.5, OM 2.4 0.4, and P = 2.5
0.01 pmoles ANF/g tissue. These values are very similar to
those previously reported by our laboratory in the same prep-
aration [8, 17]. The density of ANF receptors in hypertrophied
kidneys were: C = 5.7 0.8, OM = 1.8 0.2, and P = 2.4
0.2 pmoles ANF/g tissue, values not significantly different (P>
0.05) from the corresponding density of ANF receptors in
control rats.
Table 2 shows the effects of ANF,28 on absolute values 01
renal function parameters in control (N = 6), and hypertrophied
(N = 5) filtering isolated kidneys. Figure 3 shows the relative
dose-related changes in GFR and UNaV in these kidneys. In
control and hypertrophied kidneys, ANF led to dose-related
increases in GFR, RVR, V, UNV, UKV, FENa and FEK. In
both groups of animals, increases in parameters of renal func-
tion were already detectable at the lowest perfusate concentra-
tions of ANF128 (100 pM), and maximal effects were obtained
between 1 and 10 nM of the peptide. The ED50 of the renal
effects of ANF,28 was approximately 0,5 nM. At concentra-
tions above 10 flM of ANF, GFR tended to fall towards control
levels in both groups, a phenomenon that was accompanied by
a slight fall in sodium excretion. It is likely that the decrease in
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Fig. 1. Dose response effects of ANF,.28 on sodium excretion (A) and
glomerular filtration rate (B) in uninephrectomized and control whole
rat experiments. After control periods, ANF,28 was administered to
hypertrophied (•, N = 6) and control (0, N = 5) at sequential infusion
rates of 0.02, 0.1, and 1.0 gImin/kg body wt immediately after bolus
injections of 0.2, 1.0, and 10 zg/kg body wt, respectively. Values (mean
SE) are expressed as differences () from control periods. Table 1
contains absolute values of the dose-response effects of ANFI28 on
UN,V and GFR as well as other measured renal functional parameters.
B
0
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Fig. 2. Density of ANF receptors in cortex (C) outer medulla (OM),
and papilla (P) in hyperirophied (D) and control (D) isolated perfused
rat kidneys. The density of ANF receptors (pmollg tissue) was deter-
mined in non-filtering isolated perfused rat kidneys by equilibrium
binding with saturating concentrations of '251-ANF128 as described in
Methods. Results are mean SE. The densities of ANF receptors in
hypertrophied kidneys (N = 4) were not significantly different (P >
0.05) from those in control kidneys.
GFR at the high compared to low concentrations of ANF is due
to an increase in tubular pressure, resulting from the marked
sustained increase in urine flow rate (Table 2). A similar, albeit
less pronounced, tendency was apparent at the highest dose of
ANF in whole animal studies in control rats (Table 1). The
absolute and relative dose-related changes in renal function
parameters in hypertrophied kidneys were indistinguishable (P
> 0.05) from those in control kidneys, demonstrating that the
hypertrophied kidney has a preserved responsiveness to the
effects of ANF.
Figure 4 shows the perfusate decay curves of TCA precipi-
table radioactivity in control (N =4) and hypertrophied (N = 4)
non-filtering isolated kidneys after the addition of 1251-ANF128
to the perfusate. HPLC analysis of perfusate samples shows
that TCA precipitable radioactivity corresponds to intact 1251
ANF128 (data not shown), confirming our previous observation
in this regard [17]. In both control and hypertrophied kidneys
perfusate concentrations of TCA precipitable radioactivity
reached similar and near steady values between 20 and 30
minutes of perfusion. This demonstrates that equilibrium bind-
ing has been achieved in hypertrophied and control kidneys.
The organ clearance of labeled ANF, calculated from the initial
rate constant (first 15 mm) of the exponential perfusate decay of
TCA precipitable radioactivity was 2.82 0.44 mI/mm in
hypertrophied kidneys, a value that was not significantly differ-
ent (P > 0.05) from that of control kidneys (3.14 0.24 mI/mm).
Of note is that in control and experimental kidneys, the organ
clearance was almost one order of magnitude greater than the
GFR (compare with values in Table 2).
Discussion
In compensatory renal hypertrophy there is an increase in
kidney mass, which is accompanied by an increase in GFR and
electrolyte excretion to compensate for the loss of the contra-
lateral kidney and maintain volume homeostasis [20, 21]. To our
knowledge, there had been no previous studies on ANF effects
and receptors during the rapid increase in kidney mass and
function of the contralateral kidney following uninephrectomy.
The present in vivo studies confirm previous observations of
increased mass and baseline renal functions one week after
contralateral nephrectomy, and demonstrate for the first time
that there is an enhanced responsiveness of the hypertrophied
kidney to the effects of ANF in vivo. When the hypertrophied
kidney is removed from the animal and perfused in vitro,
baseline values for GFR and electrolyte excretion and dose-
response curve of the effects of ANF were indistinguishable
from those in isolated control kidneys. Data in the isolated
hypertrophied kidney demonstrate that ANF receptor number
increases in nearly exact proportion to kidney weight. This
preserves the responsiveness of the hypertrophied isolated
kidney to ANF and also results in normal receptor-mediated
clearance of hormone by the hypertrophied kidney.
We have previously demonstrated that the methodology to
determine specific binding of ANF in whole kidney and its
regions (cortex, medulla, papilla) measures authentic binding of
the hormone to both major classes of ANF renal receptors (the
reader is referred to reference [17] for the detailed data and
complete discussion of this methodology). In the present study,
the density of ANF receptors was determined by the equilib-
rium binding of a single saturating dose of radioligand. Because
more than 95% of the total ANF receptor population in whole
rat kidney, kidney cortex, and outer medulla is constituted by
C-ANF receptors [81, the present experiments demonstrate that
the density of this class of ANF receptors remains stable during
kidney growth. In view of the overwhelming proportion of
C-ANF receptors in relation to B-ANF receptors in cortex and
outer medulla, changes in the density of B-ANF receptors in
these regions cannot be detected by ligand-binding experi-
ments. However, the ED50 and the maximal effects of ANF,
which are mediated by BA-ANF receptors, were also not
substantially different in control and hypertrophied kidneys
(Table 2). Although dose-response characteristics are deter-
mined by both receptor and post-receptor events, this finding
suggests that there is not a substantial increase in B-ANF
receptor density in hypertrophied kidneys. In the renal papilla,
which has an almost equal proportion of C-ANF and BA-ANF
receptors [8], the density of the total population of ANF
receptors in hypertrophied kidneys also remained unchanged.
The lack of changes in the density and distribution of ANF
receptors in hypertrophied kidney necessarily implies that there
is an increase in the number of membrane BA-ANF and C-ANF
receptors that is almost exactly proportional to the increase in
kidney weight and, by inference, to the increase in total protein
synthesis that occurs in compensatory hypertrophy [20, 21].
Previous data in the isolated perfused rat kidney have shown
that receptor-mediated removal of ANF from the perfusate is
very marked, greatly exceeding the filtration of the peptide 1171.
The receptors involved in this process are C-ANF receptors,
mostly localized in glomerular and vascular structures of the
kidney [8, 10]. Since the present results show that the density of
C-ANF receptors is not altered in the hypertrophied kidney
compared to controls, it is not surprising that the organ clear-
ance of ANF during kidney compensatory growth is not signif-
icantly different from that of control kidneys. We have previ-
ously demonstrated that C-ANF receptors play a major role in
the removal of ANF from plasma [101. Thus, preserved C-ANF
receptor-mediated clearance of ANF is likely to account, at
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Table 2. Cumulative dose-response effects of ANF1_28 in control and hypertrophied isolated perfused rat kidneys
ANF1.28
M
V
jd/min
GFR
ml!min FF
RVR
mm Hg!
ml!min
UN.V UKV FEN FE
p.Eq!min %
Controls (N = 6)
0
10-10lO
10—8
l0—
28.4 6.1
94.6 16.2
212.6 32.4
229.2 40.7
149.6 14.1
0.47 0.06
0.67 0.07
0.85 0.10
1.05 0.21
0.65 0.11
0.0139 0.004
0.0237 0,002
0.0299 0.001
0.0362 0.005
0.0219 0.002
3.3 0.4
3.5 0.4
3.9 0.3
3.9 0.3
3.8 0.4
1.19 0.47
4.34 1.50
13.94 2.40
15.79 2.30
10.07 0.99
0.37 0.11
1.00 0.15
2.17 0.27
2.08 0.31
1.30 0.20
1,81 0.6
4.59 1.4
11.62 1.8
10.73 1.1
13.09 3.8
23.1 8.8
42.0 10.9
75.6 13.7
63.8 11.2
83.8 30.3
Hypertrophied (N = 5)
0l0'°l0
108l0
14.9 2.1
53.4 9.1
189.7 25.1
193.6 30.7
145.1 43.0
0.36 0.01
0.68 0.05
1.08 0.16
0.88 0.13
0.72 0.13
0.0106 0.001
0.0192 0.001
0.0301 0.003
0.0243 0.002
0.0206 0.004
2.5 0.3
2.8 0.3
3.3 0.2
3.2 0.3
3.1 0.3
0.42 0.14
1.76 0.67
11.73 2.24
12.41 3.41
9.89 5.16
0.17 0.07
0.60 0.12
2.25 0.18
1.92 0.13
1.22 0.34
0.80 0.3
1.73 0.6
7.82 1.2
9.91 2.7
7.37 2.9
11.2 4.6
21.2 3.5
54.8 4.3
60.8 4.8
46.1 8.6
Values are mean SE of 6 control and 5 hypertrophied kidneys. Abbreviations are: 0, control periods before the addition of ANF128; V, urine
flow rate; GFR, glomerular filtration rate; FF, filtration fraction; RVR, renal vascular resistance; UNV and UKV, urinary excretion rates of sodium
and potassium, respectively; FENa and FEK, fractional urinary excretion of sodium and potassium, respectively.
least in part, for the present finding that plasma levels of ANF
are not altered in compensatory hypertrophy.
Regulation of surface expression of ANF receptors by ho-
mologous (ligand-induced) stimuli was not expected to occur in
the present experiments, because plasma levels of ANF were
unaltered in uninephrectomized rats. The finding that the num-
ber of ANF receptors in hypertrophied kidneys increase in
exact proportion to kidney weight demonstrates further that the
specific synthesis of ANF receptors is fully responsive to the
stimuli that increase overall renal protein synthesis in compen-
satory renal hypertrophy. Results of studies on regulation of
ANF receptors in physiological or pathological conditions have
provided contradictory evidence. Initial studies in glomeruli
removed from rats fed a high salt diet suggested a decreased
density (down regulation) of C-ANF but not BA-AN F receptors
[13]. Subsequent studies in the same preparation by the same
group of investigators showed that the apparent down-regula-
tion was due to a higher occupancy rather than true under
expression of surface receptors [121. Another group of investi-
gators, however, claimed that there is indeed down regulation
of C-ANF but not BA-ANF receptors in isolated glomeruli
removed from rats fed a high salt diet [221. Our group has
reported that the density of ANF receptors in isolated kidneys
removed from rats fed a high salt diet did not differ significantly
from that in rats fed a low salt diet [23]. In congestive heart
failure of the cardiomyophatic hamster, one group of investiga-
tors [24] reported down regulation of B-ANF receptors in
glomeruli, whereas other investigators [25, 26] failed to detect
either up or down regulation of glomerular ANF receptors in
the same preparation. In models of DOCA-salt hypertension,
up regulation of papillary BA-ANF receptors and down regula-
tion of glomerular ANF receptors have been reported [15]. On
the other hand, reduced binding sites of ANF in the papilla have
been found in the spontaneously hypertensive rat (SHR) model
[27]. Many of these apparently contradictory results are due to
technical difficulties, and to the fact that, when present, up or
down regulation of ANF receptors is quantitatively small com-
pared to that reported to occur for other hormone receptors. In
general, marked up or down regulation is not a prevalent
characteristics of ANF receptors. For C-AN F receptors, lack
of significant homologous down regulation is likely due to the
rapid recycling of internalized C-ANF receptors to the cell
surface [28]. We have recently shown that, contrary to C-ANF
and other polypeptide hormone receptors, the BA-ANF recep-
tor in cultured glomerular mesangial and renomedullary inter-
stitial cells is a membrane resident protein that is not internal-
ized upon ligand binding [29]. Since down regulation is usually
due to hydrolysis of internalized receptor-ligand complexes in
lysosomes [30], this intrinsic characteristic may account for the
lack of homologous down regulation of B-ANF receptors.
ANF has been reported to have a growth-inhibitory effect in
rat glomerular mesangial cells in culture that is elicited by a
B-ANF receptor-mediated generation in cGMP [31]. Because
we could not detect a change in receptor density or sensitivity
to ANF in the hypertrophied isolated kidney, the compensatory
hypertrophy does not seem to be facilitated by a down regula-
tion of B-ANF receptors or an up regulation of C-ANF recep-
tors. Alternatively, the present experiments do not exclude the
possibility that kidney growth would still be greater if it were
not for a putative growth-inhibitory effect of ANF.
Recently, a new subtype of B-ANF receptors, the B (or
GCB)-ANF receptor has been discovered [32, 33]. This receptor
also mediates the generation of cGMP, but CNP rather than
ANF is its major physiological ligand [34]. In the present
experimental design, which used native ANF as a ligand, we
would have been unable to detect a putative regulation of
BB-ANF receptor during renal growth. It is unlikely, however,
that BB-ANF receptors are functionally expressed in the rat
kidney under normal conditions, because we failed to observe
any effect of CNP on renal function parameters in the isolated
rat kidney, even at concentrations as high as 1 M (J. Okoli-
cany, D. Price, 0. Koh and T. Maack, unpublished observa-
tions).
One of the noteworthy findings of the present experiments is
that when the hypertrophied kidney is perfused in vitro it does
not keep a memory of the higher baseline values of GFR and
electrolyte excretion or of the hyperresponsiveness to admin-
istered ANF. Indeed, the sensitivity and maximal response of
the hypertrophied kidneys to the effects ANF was unchanged
from controls. This is in contrast with the in vivo findings that
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I \ phied isolated rat kidneys. Decay curves in four control (0) and four• hypertrophied (•) non-filtering isolated perfused rat kidneys were
determined by the perfusate concentration of TCA precipitable
i (TCAppt) 1251-radioactivity (ordinate) at several time intervals (abscis-
sa) after the addition of '251-ANF128, as described in Methods. The
differences between hypertrophied and control kidneys at each time
point (mean SE) were not significantly different (P> 0.05). From theC exponential decay curves in the first 15 minutes of perfusion, the organ
clearances of '251-ANF1 25 were calculated (Methods) and the results are
given in the text.
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Fig. 3. Dose response effects of ANF,28 on sodium excretion (A),
glomerular filtration rate (B) and renal vascular resistance (C) in
hypertrophied () and control (0) isolated perfused rat kidneys. After
control periods, ANF128 was added sequentially to the perfusate of
hypertrophied (N = 5) and control (N = 6) isolated perfused rat kidneys
to give final concentrations of 10b0 to lO M. Values (mean SE) are
expressed as differences () from control periods. Table 2 contains
absolute values of the dose-response effects of ANF128 on sodium
excretion (UNaV) and GFR as well as other measured renal functional
parameters. * P < 0.05 vs. zero.
show higher baseline values, and enhanced responses to the
effects of administered ANF on GFR and sodium excretion.
The receptor studies in the isolated preparation indicate that
these adaptations of the hypertrophied kidney in vivo are not
due to over-expression (up regulation) of biological (B-ANF)
receptors or an under-expression (down regulation) of clear-
ance (CANF) receptors. The higher baseline GFR and sodium
excretion values, and the hyperresponsiveness to administered
ANF must be due to conditions that prevail in the whole animal,
and are absent in the isolated kidney preparation, This suggests
that systemic humoral or autonomic nervous factors contribute
significantly to the increase in GFR and sodium excretion in
compensatory renal hypertrophy. In this regard, it is possible,
even likely, that autonomic regulation of blood flow, which is
absent in the isolated kidney, plays an important role in the
adaptative increase in GFR and sodium excretion. Further
studies are needed to precisely identify the nature of the
nervous or humoral factors that contribute to the adaptive renal
responses in compensatory hypertrophy. Whatever the case,
however, a preserved and even enhanced responsiveness to
ANF may be essential for an adequate regulation of extracel-
lular volume and sodium balance in compensatory hypertrophy.
In conclusion, the results of the present study demonstrate
that the two major classes of ANF receptors adapt to renal
growth by increasing their number in exact proportion to the
increase in kidney weight. In the isolated kidney, this leads to
preserve i responsiveness of the hypertrophied kidney to the
effects of ANF, and preserved organ clearance of the hormone.
In addition, the hypertrophied kidney in vivo has an enhanced
responsiveness to ANF, which results from autonomic nervous
or humoral factors that are absent in the isolated preparation.
The normal intrinsic renal adaptation of ANF receptors, to-
gether with systemic factor that favor a greater effect of ANF
on GFR and sodium excretion may contribute importantly to
the maintenance of sodium volume homeostasis in compensa-
tory hypertrophy.
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